MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.*1 For the first time in LVAD history, 5-year data is available from this prospective randomized LVAD trial.2 LVAD data was presented at the European Society of Cardiology Annual Meeting (ESC 2022).
The ELEVATE Registry evaluated the real-world experience of the HeartMate 3 LVAD in a post-approval setting.5
*HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
**Patients on inotropes who did not receive a transplant or left ventricular assist device.